Obstructive Hypertrophic Cardiomyopathy Clinical Trial
Official title:
Acute Hemodynamic Effects of Continous Positive Airway Pressure (CPAP) in Patients With Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease, is a cause of disability including heart failure, atrial fibrillation, and sudden death, with an annual mortality varying from 1% to 6%. Obstructive sleep apnea (OSA) is extremely common among patients with established cardiovascular disease, including hypertension and atrial fibrillation and when present may contribute to worse cardiovascular outcome. Although patients with HCM do not necessarily have typical characteristics of patients with OSA, such as obesity and increasing age, there is recent evidence that OSA is extremely common among patients with HCM, with a prevalence ranging from 32% to 71%. The presence of OSA among patients with HCM is independently associated with worse structural and functional impairment of the heart, including atrial and aorta enlargement, worse New York Heart Association functional class, and worse quality of life. Therefore, the recognition and treatment of OSA is a new area of research that may impact in the management of patients with HCM.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06023186 -
Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM
|
||
| Completed |
NCT05726799 -
Use of Cryoenergy to Faciltate Myectomy in Hypertrophic Obstructive Cardiomyopathy: Comparison With the Classical Approach
|
||
| Active, not recruiting |
NCT03723655 -
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
|
Phase 2/Phase 3 | |
| Completed |
NCT04603521 -
Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)
|
||
| Active, not recruiting |
NCT06211595 -
Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy
|
N/A | |
| Recruiting |
NCT06116968 -
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
|
Phase 3 | |
| Completed |
NCT03470545 -
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
|
Phase 3 | |
| Recruiting |
NCT05879523 -
A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy
|
Phase 1 | |
| Not yet recruiting |
NCT06146660 -
A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
|
||
| Recruiting |
NCT05771987 -
Permanent Pacing for Drug-refractory Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
|
N/A | |
| Active, not recruiting |
NCT05174416 -
A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
|
Phase 3 | |
| Not yet recruiting |
NCT06224621 -
Percutaneous Endocardial Septal Radiofrequency Ablation in Obstructive Hypertrophic Cardiomyopathy
|
N/A | |
| Not yet recruiting |
NCT06368037 -
Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy
|
N/A | |
| Recruiting |
NCT05489705 -
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive HCM)
|
||
| Recruiting |
NCT06354556 -
Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04783766 -
Safety, Tolerability and Pharmacokinetics Study of CK-3773274
|
Phase 1 |